Zentiva AG Seeks Merger Squeeze-Out of APONTIS PHARMA AG's Minority Shareholders

On March 5, 2025, Zentiva AG formally requested a merger squeeze-out of minority shareholders in APONTIS PHARMA AG. This move aligns with the German Transformation Act and Stock Corporation Act, aiming to consolidate all shares under Zentiva's majority holdings. Currently, Zentiva controls approximately 93.83% of APONTIS PHARMA's share capital. The request includes a merger agreement proposal between the two companies, necessitating approval from APONTIS PHARMA's Annual General Meeting.

The specifics of the cash compensation offered to minority shareholders will be disclosed at a later date by Zentiva. APONTIS PHARMA plans to announce the date for the Annual General Meeting, where the decisive transfer resolution will be voted upon. This development marks a significant step towards further integration between Zentiva and APONTIS PHARMA.